AlzeCure Pharma
5.10.2021 10:16:39 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 5, 2021 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company's presentation and poster regarding the research platform in neurology, NeuroRestore, its connection to BDNF/TrkB signaling and potential therapeutic role in depression, as presented at the European College of Neuropsychopharmacology (ECNP) 2021 on 2-5 October in Lisbon, Portugal, are now available in its entirety on the company's website.
The abstract, titled Characterization of positive allosteric modulators of TrkB for the treatment of depression , was presented by Johan Sandin, Chief Scientific Officer, and contains new data showing how substances from the NeuroRestore platform affect relevant signaling pathways in the brain and have effects in various preclinical models that link to depression.
These substances stimulate signaling through the receptors for the neurotrophin BDNF, so-called TrkB receptors. This biological system has been linked to depression, and the support for this hypothesis has been further strengthened in recent times and new scientific findings indicate that many of the classic antidepressant drugs available today actually mediate their effect via BDNF/TrkB*. In addition, the substances also show a positive effect on cognitive ability, such as memory and learning - functions that can also be affected in depression.
"NeuroRestore, with the primary candidate drug ACD856, acts as a BDNF/NGF signaling enhancer and can be used in various types of cognitive impairments in which the same signal pathway is reduced. We have previously seen that NeuroRestore compounds have had significant effects in preclinical models of depression and it is very exciting that we, with these findings, get further scientific support for the effect," said Johan Sandin, CSO at AlzeCure Pharma.
"The findings we have seen with our substances indicate that there are also great opportunities for the NeuroRestore platform in other cognitive disorders outside Alzheimer's. Depression is an area with great medical needs and affects people at a young age," said Martin Jönsson, CEO of AlzeCure Pharma.
The authors of the abstract include Johan Sandin, Chief Scientific Officer at AlzeCure, Dr. Pontus Forsell, Head of Discovery, Dr. Gunnar Nordvall, Head of Chemistry and Magnus Halldin, Head of DMPK & Safety at AlzeCure.
The presentation, the poster and the abstract are available on AlzeCure's website: ( https://www.alzecurepharma.se/en/presentations-and-interviews/ ).
*) Casarotto et al., 2021, Antidepressant drugs act by directly binding to TRKB neurotrophin receptors, Cell 184, 1299-1313, March 4, 2021, https://www.cell.com/cell/pdf/S0092-8674(21)00077-5.pdf
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
About NeuroRestore
NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep apnea, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. In preclinical studies with NeuroRestore we have been able to show that our drug candidates enhance communication between the nerve cells and improve cognitive ability. NeuroRestore stimulates specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders. There is also a link between BDNF signaling and depression, something that has been further strengthened in recent years.
About Alzheimer's disease
Alzheimer's disease is the most common form of dementia, affecting approximately 50 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute. The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $15 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined.
Image Attachments
Martin Jönsson CEO And Johan Sandin CSO AlzeCure Pharma
Attachments
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/666797/New-Data-Showing-the-Potential-of-the-NeuroRestore-Project-in-Depression-Presented-at-ECNP-2021-Conference
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Redington MD and Group CEO V.S. Hariharan Appointed to GTDC Executive Committee12.5.2026 15:00:00 CEST | Press release
GTDC appointed V.S. Hariharan, Managing Director and Group CEO of the Redington Group, to its Executive Committee (EC) to guide strategy and provide operational oversight. The EC advances the organization's mission to educate, advocate, and influence the tech industry on the evolving role of IT distribution worldwide. Mr. Hariharan leads Redington's $11.8 billion distribution and supply chain business across 40 markets. Redington continues to strengthen its role as a Technology Orchestrator, enabling seamless connections across the ecosystem to Unlock Next opportunities for partners. TAMPA, FL / ACCESS Newswire / May 12, 2026 / The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, named V.S. Hariharan, Managing Director and Group CEO of Redington Limited, to its Executive Committee. The committee provides operational oversight and helps guide GTDC's long-term strategy, advancing the organization's mission to strengthen distributio
Braiin Advances Proposed Acquisition of Home.cc with Valuation and Growth-Capital Components Totaling Approximately A$73 Million to Build AI-Native LivTech Platform for Residential Lifecycle Services, Targeting the $3+ Trillion Global Residential Lifecycle Services Market12.5.2026 14:15:00 CEST | Press release
Proposed acquisition would combine Home's embedded residential distribution, payments infrastructure and household-services platform with Braiin's AI, CXaaS and PropTech ecosystem MELBOURNE, AU AND LONDON, UK / ACCESS Newswire / May 12, 2026 / Braiin Limited (NASDAQ:BRAI) ("Braiin" or the "Company"), a global AI platform company delivering automation and predictive analytics across precision agriculture, customer experience and property technology, today announced that it has entered into a non-binding term sheet to advance its proposed acquisition of Home.cc ("Home"), a Living Technology ("LivTech") platform focused on embedded residential distribution, household service activation, payments and connected living infrastructure. Under the proposed structure, Braiin would acquire a 50.1% majority interest in Cumbria Capital Ltd, the parent company of Home.cc, through a share purchase to be satisfied by the issuance of Braiin equity securities. The non-binding term sheet contemplates a p
Polaris Renewable Energy Announces Approval of SO1 Agreement by FOMB12.5.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 12, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that, on May 8, 2026, the Financial Oversight and Management Board of Puerto Rico ("FOMB") approved the Battery Energy Storage System ("BESS") Standard Offer Agreement ("SO1 Agreement"). The approval of the FOMB completes the three-steps approval process for the SO1 Agreement, following prior regulatory approvals obtained from the Puerto Rico Energy Bureau ("PREB") and the Governing Board of the Puerto Rico Electric Power Authority ("PREPA"). The SO1 Agreement is intended to be executed between PREPA and Polaris Power US, Inc ("PPUS"), a wholly owned subsidiary of Polaris. The SO1 Agreement forms part of the Puerto Rico Accelerated Storage Addition Program ("ASAP"), a strategic initiative aimed at strengthening grid reliability across the island through the deployment of utility-scale BESS co-located with existing generation facilities. Under this
Elixir Technologies Unveils Elixir Muse: The AI Writing Assistant Built for Total Data Privacy12.5.2026 13:00:00 CEST | Press release
Elixir's new writing assistant product delivers AI-powered drafting, revision, translation, validation, tone of voice and sentiment analysis, and compliance analysis - without storing, harvesting or training on user data. OJAI, CA / ACCESS Newswire / May 12, 2026 / Elixir Technologies today introduced Elixir Muse™, a privacy-first AI writing assistant that significantly minimizes the workload involved in drafting, editing, proofreading and translating text. Powered by Elixir Ai, the company's proprietary AI technology, Elixir Muse™ assists both writers and content creators improve the quality, clarity and consistency of their written content through advanced AI features - all while safeguarding the privacy of user data. Elixir Muse™ introduces a fundamentally different approach to AI-assisted document iteration: one where privacy and control are prioritized from the start, rather than being an afterthought. With user-friendly writing features and proven use cases, the product functions
Dubai Health and AGFA HealthCare Mark 20 Years of Collaboration Supporting Dubai's Healthcare System12.5.2026 11:30:00 CEST | Press release
Dubai Health and AGFA HealthCare have marked 20 years of collaboration supporting Dubai's healthcare system, reflecting a shared commitment to advancing integrated, patient-centered care. DUBAI, AE / ACCESS Newswire / May 12, 2026 / Over the past two decades, AGFA HealthCare has supported Dubai's healthcare system - most recently contributing to Dubai Health's integrated academic health system across care, learning, and research through a shared digital foundation. It enables clinicians access to critical information while maintaining data security, operational continuity, and patient confidentiality, and supports large-scale screening services in high-volume settings. The partnership has progressed from digitizing diagnostic imaging into a comprehensive enterprise imaging, analytics, and AI ecosystem that supports multiple clinical specialties, leadership decision-making, and population-scale healthcare services across Dubai Health's expanding network. Atif Al Braiki, Chief Digital an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom